Scottish MS patients finally given access to oral MS drug Gilenya®

The Scottish Medicines Consortium (SMC) has today announced that Gilenya® (fingolimod), the world’s first pill for the treatment of highly active relapsing-remitting multiple sclerosis (RRMS), has now been approved for restricted use within NHS Scotland.
Today’s decision means that people with highly active RRMS not responding to treatment with first-line interferon injections now have the option of switching to fingolimod as their next ...